Inovio Pharmaceuticals(US:INO) TMX Newsfile·2026-03-09 22:07Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals, Inc. due to allegations of violations of federal securities laws related to misleading statements and inadequate disclosures regarding the company's product development and regulatory prospects [2][4]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses in Inovio to contact them directly to discuss their legal options [1]. - There is a deadline of April 7, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Inovio [2]. - The complaint alleges that Inovio and its executives made false statements regarding the manufacturing of the CELLECTRA device and the prospects of the INO-3107 Biologics License Application (BLA) [4]. Group 2: Regulatory Developments - On December 29, 2025, the FDA accepted Inovio's BLA for INO-3107 for standard review but noted that the company did not provide sufficient information for accelerated approval [5]. - Inovio announced it does not plan to pursue approval under the standard review timeline and will seek a meeting with the FDA to discuss options for accelerated approval [5]. Group 3: Market Reaction - Following the FDA's announcement, Inovio's stock price fell by $0.56 per share, representing a decline of 24.45%, closing at $1.73 per share on December 29, 2025 [6].